Smoking is associated with increased free testosterone and fasting insulin levels in women with polycystic ovary syndrome, resulting in aggravated insulin resistance

Fertility and Sterility

Volumn 94, Issue 2, 2010, Pages 673-677

  Cupisti, Susanne ^a   Häberle, Lothar ^b   Dittrich, Ralf ^a   Oppelt, Patricia G ^a   Reissmann, Christine ^a   Kronawitter, Desiree ^a   Beckmann, Matthias W ^a   Mueller, Andreas ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Hyperandrogenism; insulin resistance; PCOS; smoking

Indexed keywords

INSULIN; TESTOSTERONE;

ACNE; ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; BODY HEIGHT; BODY WEIGHT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIRSUTISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MENSTRUATION; OLIGOMENORRHEA; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; OVULATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SMOKING; TESTOSTERONE BLOOD LEVEL;

ADOLESCENT; ADULT; BODY MASS INDEX; COHORT STUDIES; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HIRSUTISM; HOMEOSTASIS; HUMANS; HYPERANDROGENISM; INSULIN; INSULIN RESISTANCE; OVULATION; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; SMOKING; TESTOSTERONE; YOUNG ADULT;

EID: 77953715967     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.03.062     Document Type: Article

References (39)

1. Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Futterweit W., et al. Androgen Excess Society. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91 (2006) 4237-4245
2. Centers for Disease Control and Prevention (CDC). State-specific smoking-attributable mortality and years of potential life lost-United States, 2000-2004. MMWR Morb Mortal Wkly Rep 58 (2009) 29-33
3. Gu D., Kelly T.N., Wu X., Chen J., Samet J.M., Huang J.F., et al. Mortality attributable to smoking in China. N Engl J Med 360 (2009) 150-159
4. Norman R.J., Davies M.J., Lord J., and Moran L.J. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 13 (2002) 251-257
5. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 89 (2008) 505-522
6. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
7. Zawadzki J.K., and Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A., Givens J.R., Haseltine F.P., and Merriam G.R. (Eds). Polycystic ovary syndrome (1992), Blackwell Scientific, Boston 377-384
8. Archer J.S., and Chang R.J. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 18 (2004) 737-754
9. Souter I., Sanchez L.A., Perez M., Bartolucci A.A., and Azziz R. The prevalence of androgen excess among patients with minimal unwanted hair growth. Am J Obstet Gynecol 191 (2004) 1914-1920
10. Rosner W., Auchus R.J., Azziz R., Sluss P.M., and Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 92 (2007) 405-413
11. Vermeulen A., Verdonck L., and Kaufman J.M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84 (1999) 3666-3672
12. Mueller A., Cupisti S., Binder H., Hoffmann I., Kiesewetter F., Beckmann M.W., et al. Endocrinological markers for assessment of hyperandrogenemia in hirsute women. Horm Res 67 (2007) 35-41
13. Mueller A., Dittrich A., Cupisti S., Beckmann M.W., and Binder H. Is it necessary to measure free testosterone to assess hyperandrogenemia in women? The role of calculated free and bioavailable testosterone. Exp Clin Endocrinol Diabetes 114 (2006) 182-187
14. Mueller A., Dittrich R., Binder H., Hoffmann I., Beckmann M.W., and Cupisti S. Endocrinological markers for assessing hyperandrogenemia in women classified as having polycystic ovary syndrome (PCOS) according to the revised 2003 diagnostic criteria. Eur J Med Res 11 (2006) 540-544
15. Mueller A., Cupisti S., Binder H., Hoffmann I., Beckmann M.W., and Dittrich R. The role of albumin in the calculation of free and bioavailable testosterone in women with hyperandrogenemia. In Vivo 20 (2006) 403-407
16. Mueller A., Gooren L.J., Naton-Schötz S., Cupisti S., Beckmann M.W., and Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. J Clin Endocrinol Metab 93 (2008) 1408-1411
17. Norman R.J., Dewailly D., Legro R.S., and Hickey T.E. Polycystic ovary syndrome. Lancet 370 (2007) 685-697
18. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
19. Katz A., Nambi S.S., Mather K., Baron A.D., Follmann D.A., Sullivan G., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85 (2000) 2402-2410
20. Matsuda M., and DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22 (1999) 1462-1470
21. Radikova Z., Koska J., Huckova M., Ksinantova L., Imrich R., Vigas M., et al. Insulin sensitivity indices: a proposal of cut-off points for simple identification of insulin-resistant subjects. Exp Clin Endocrinol Diabetes 114 (2006) 249-256
22. Cupisti S., Dittrich R., Binder H., Beckmann M.W., and Mueller A. Evaluation of biochemical hyperandrogenemia and body mass index in women presenting with amenorrhea. Exp Clin Endocrinol Diabetes 115 (2007) 298-302
23. Ascaso J.F., Pardo S., Real J.T., Lorente R.I., Priego A., and Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 26 (2003) 3320-3325
24. Hrebícek J., Janout V., Malincíková J., Horáková D., and Cízek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metab 87 (2002) 144-147
25. Cupisti S., Kajaia N., Dittrich R., Duezenli H., Beckmann M W., and Mueller A. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome. Eur J Endocrinol 158 (2008) 711-719
26. Cupisti S., Dittrich R., Binder H., Kajaia N., Hoffmann I., Maltaris T., et al. Influence of body mass index on calculated androgen parameters in adult women with hirsutism and PCOS. Exp Clin Endocrinol Diabetes 115 (2007) 380-386
27. Kajaia N., Binder H., Dittrich R., Oppelt P.G., Flor B., Cupisti S., et al. Low sex hormone-binding globulin as a predictive marker for insulin resistance in women with hyperandrogenic syndrome. Eur J Endocrinol 157 (2007) 499-507
28. Mathur R.S., Moody L.O., Landgrebe S., and Williamson H.O. Plasma androgens and sex hormone-binding globulin in the evaluation of hirsute females. Fertil Steril 35 (1981) 29-35
29. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57 (1995) 289-300
30. Mendelson J.H., Sholar M.B., Mutschler N.H., Jaszyna-Gasior M., Goletiani N.V., Siegel A.J., et al. Effects of intravenous cocaine and cigarette smoking on luteinizing hormone, testosterone, and prolactin in men. J Pharmacol Exp Ther 307 (2003) 339-348
31. Ponholzer A., Plas E., Schatzl G., Struhal G., Brössner C., Mock K., et al. Relationship between testosterone serum levels and lifestyle in aging men. Aging Male 8 (2005) 190-193
32. Funabashi T., Sano A., Mitsushima D., and Kimura F. Nicotine inhibits pulsatile luteinizing hormone secretion in human males but not in human females, and tolerance to this nicotine effect is lost within one week of quitting smoking. J Clin Endocrinol Metab 90 (2005) 3908-3913
33. Smith L.M., Cloak C.C., Poland R.E., Torday J., and Ross M.G. Prenatal nicotine increases testosterone levels in the fetus and female offspring. Nicotine Tob Res 5 (2003) 369-374
34. Somm E., Schwitzgebel V.M., Vauthay D.M., Camm E.J., Chen C.Y., Giacobino J.P., et al. Prenatal nicotine exposure alters early pancreatic islet and adipose tissue development with consequences on the control of body weight and glucose metabolism later in life. Endocrinology 149 (2008) 6289-6299
35. Ray R., Tyndale R.F., and Lerman C. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet 23 (2009) 1-10
36. Enea C., Boisseau N., Diaz V., and Dugué B. Biological factors and the determination of androgens in female subjects. Steroids 73 (2008) 1203-1216
37. Chiolero A., Faeh D., Paccaud F., and Cornuz J. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr 87 (2008) 801-809
38. Yilmaz M., Bukan N., Ersoy R., Karakoç A., Yetkin I., Ayvaz G., et al. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. Hum Reprod 20 (2005) 2414-2420
39. Chelland Campbell S., Moffatt R.J., and Stamford B.A. Smoking and smoking cessation-the relationship between cardiovascular disease and lipoprotein metabolism: a review. Atherosclerosis 201 (2008) 225-235